MedTrace Logo

Alcohol Brief Intervention Plus Personalized Mobile Chat-based Intervention to Reduce Alcohol Misuse in an Emergency Department

NCT03823599 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-26

No results posted yet for this study

Summary

This project focuses on patients in AED. Objectives of this project are:

1. To examine the factors associated with alcohol drinking and alcohol use disorder
2. To examine the effect of face-to-face alcohol brief intervention on drinking reduction
3. To examine the effect of a continuous interactive chat-based intervention via "WhatsApp" on drinking reduction
4. To explore the perception of face-to-face alcohol brief intervention
5. To explore the perception of continuous interactive chat-based intervention via instant messaging mobile application "WhatsApp"

Conditions

Interventions

BEHAVIORAL

Mobile chat-based instant messages

Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline

BEHAVIORAL

Alcohol brief intervention

The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Man Ping Wang, PhD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-04-30
Completion
2019-05-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03823599 on ClinicalTrials.gov